Press release
Investigation announced for Investors in shares of Evolus, Inc. (NASDAQ: EOLS)
An investigation for investors in Evolus, Inc. (NASDAQ: EOLS) shares over potential securities laws violations by Evolus, Inc. was
Investors who purchased shares of Evolus, Inc. (NASDAQ: EOLS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Evolus, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Newport Beach, CA based Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
An International Trade Commission judge issued a preliminary ruling on trade secrets action involving Evolus, Inc. on July 6, 2020. The non-binding decision sided with Allergan and its partner Medytox in finding that the Company and its South Korean partner firm Daewoong developed its Jeuveau product using stolen trade secrets. The judge recommended a 10-year ban on the importation of Jeuveau into the United States.
Shares of Evolus, Inc. (NASDAQ: EOLS) declined from $29.40 per share in April 2019, to as low as $3.00 per share on July 9, 2020.
Those who purchased shares of Evolus, Inc. (NASDAQ: EOLS) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Evolus, Inc. (NASDAQ: EOLS) here
News-ID: 2151879 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Evolus
Facial Injectable Market Is Booming So Rapidly | Evolus, Hugel, Revance
The Global Facial Injectable Market Size is estimated at $12.9 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.1% to reach $30.7 Billion by 2034.
The latest study released on the Global Facial Injectable Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Facial Injectable market study covers significant research data and proofs to be a handy resource document for…
Botulinum Toxin Market: Strong Growth Driven by Increased Healthcare | AbbVie, E …
IMR posted new studies guide on Botulinum Toxin Market Insights with self-defined Tables and charts in presentable format. In the Study you may locate new evolving Trends, Drivers, Restraints, Opportunities generated via targeting market related stakeholders. The boom of the Botulinum Toxin marketplace became specifically driven with the aid of the growing R&D spending internationally.
Some of the Top Leading Key Players:
AbbVie Inc. (U.S.), Ipsen Pharma (France), Merz Pharma (Germany),…
Flowchart Drawing Software Market Is Booming So Rapidly | Major Giants Slickplan …
HTF MI introduces new research on Global Flowchart Drawing Software covering the micro level of analysis by competitors and key business segments. The Global Flowchart Drawing Software explores a comprehensive study of various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing. Some of the major…
Flowchart Software Market to Get a New Boost | NCH Software, Evolus, Gliffy, Cin …
The Latest published market study on Worldwide Flowchart Software Market provides an overview of the current market dynamics in the Worldwide Flowchart Software space, as well as what our survey respondents all outsourcing decision-makers predict the market will look like in 2030. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify gaps and opportunities. Some of…
Online Diagram Editor Market Pegged for Robust Expansion by 2027 | Evolus, MyDra …
This Online Diagram Editor market report provides a thorough insight of the market, allowing key players to keep informed and keep their competitive advantage. It focuses on present trends by forecasting future trends, market size, and market features. Such meticulous Market Analysis creates a comprehensive picture of market policies and supports industries in making larger earnings than before. The greatest way to gain insight into the current market situation and…
Investigation announced for Long-Term Investors in shares of Evolus, Inc. (NASDA …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Evolus, Inc.
Investors who are current long term investors in Evolus, Inc. (NASDAQ: EOLS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: EOLS stocks follows a lawsuit filed against Evolus, Inc. over alleged…
